首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era
【24h】

High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era

机译:PET / CT中较高的总代谢肿瘤体积预示着利妥昔单抗时代骨髓受累的弥漫性大B细胞淋巴瘤患者的预后较差

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Bone marrow involvement (BMI) in diffuse large B cell lymphoma (DLBCL) was naively regarded as an adverse clinical factor. However, it has been unknown which factor would separate clinical outcomes in DLBCL patients with BMI. Recently, metabolic tumor volume (MTV) on positron emission tomography/computed tomography (PET/CT) was suggested to predict prognosis in several lymphoma types. Therefore, we investigated whether MTV would separate the outcomes in DLBCL patients with BMI.
机译:弥漫性大B细胞淋巴瘤(DLBCL)中的骨髓侵犯(BMI)被天真的认为是不利的临床因素。但是,尚不清楚哪个因素会区分BMI的DLBCL患者的临床结局。最近,正电子发射断层扫描/计算机断层扫描(PET / CT)上的代谢肿瘤体积(MTV)被建议预测几种淋巴瘤的预后。因此,我们调查了MTV是否可以将DLBCL合并BMI的患者的结局分开。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号